The DiaSorin Molecular Simplexa® SARS-CoV-2 Variants Direct kit is a Research Use Only (RUO) assay intended for the in vitro qualitative detection and differentiation of the mutations N501Y, E484K, E484Q and L452R present in the genome of SARS-CoV-2 in nasal and nasopharyngeal swab specimens from patients with known SARS-CoV-2 infection.
This webinar explores:
- SARS-CoV-2 variants and surveillance programs
- Simplexa® SARS-CoV-2 Variants Direct (RUO) assay description
- Liaison® MDX melting curve analysis and internal data
**For Research Use Only. Not for use in diagnostic procedures.**
There are tick-borne diseases beyond what causes Lyme disease. Different geographies have differing prevalence’s of tick-borne infections. In the northeastern USA, some of the other infectious agents are Anaplasma phagocytophilum, Babesia species and Ehrlichia species.
This talk will describe our experiences on the processes used to implement a multiplex molecular laboratory developed test (LDT) for the detection of A. phagocytophilum, Babesia spp. and Ehrlichia spp. in a clinical reference laboratory. We will discuss various testing options including assay types and ordering algorithms. Our experiences and lessons learned after implementation will be discussed, including the testing challenges we had related to COVID-19.
- Describe the various methods available for detection of Anaplasma, Babesia and Ehrlichia
- Understand the process of LDT validation
- Discuss advantages and limitations of in-house testing
To receive credit for this webinar visit Labroots
There has been a major development in the serologic diagnosis of Lyme disease. All parties agree (as before) on the paradigm of “Two Tier Testing”. The “Old” recommendation is called STTT, or Standard Two Tier Testing (ELISA reflexed to IgG and IgM WB). There are well known drawbacks and problems with this, acknowledged by the CDC and many specialists in the field. This led to the development and adoption of an improved paradigm called MTTT, or Modified Two Tier Testing. Modified Two Tiered Testing is well validated, the associated tests have been FDA cleared and they’ve been shown to perform equal to or superior to STTT in all stages of Lyme infection.
Another change is the continued appreciation of co-infections (one tick bite transmitting multiple pathogens), with implications of the types of diagnostic tests, including the available PCR tests, to be ordered in symptomatic persons following tick bites. Finally, there continues to be new emerging TBDs, including Anaplasma, Babesia, and Ehrlichia, plus further geographic spread of the more traditional well-known agents.
- Enable participants to appreciate the prevalence and epidemiology of these TBDs.
- Understand the differences between MTTT and STTT for Lyme serologic testing.
- Appreciate co-infections and the role of PCR in acute TBD panels.
Congenital cytomegalovirus (CMV) is the most frequent infectious cause of neonatal malformation in developed nations. In light of this, congenital CMV diagnostic algorithms have garnered much discussion in the medical science community.
This two part presentation will provide an update on universal screening and targeted screening for neonates as well as a discussion on different specimen sample types and their respective clinical utility, which can impact the overall clinical diagnosis.
- Describe the clinical presentation of congential CMV.
- Understand the difference between universal screening and targeted testing for congenital CMV.
- Recognize the difference in diagnostic methods and sample types for congenital CMV testing.
Ticks are currently considered to be second only to mosquitoes as vectors of human infectious diseases in the world. Each tick species has preferred environmental conditions and habitat that determine the geographic distribution of the ticks and, consequently, the risk areas for tick-borne diseases. Tick-borne diseases are becoming more frequently diagnosed as the cause of human infections as animal reservoirs and tick vectors have increased in numbers and humans have inhabited areas where reservoir and tick populations are high.
- Ensure participants understand the new MTTT testing paradigm.
- Appreciate the prevalence of co-infections with more than one pathogen.
- Provide information on test ordering and interpretations for tick-borne diseases.
This presentation will address the fundamentals of congenital CMV in prevention, diagnosis and management. We will touch on some recent research, and how we can move forward to continue reducing the impact of congenital CMV globally.
- Describe the clinical presentation of congenital CMV.
- Understand diagnosis and indications for testing and possibilities of screening.
- Recognize the opportunities for prevention, management and therapeutic strategies.
- Understand research strategies in development to reduce the global impact of congenital CMV.
This talk will cover clinical case perspectives on utilizing both molecular and serology tests for diagnosing COVID-19 active and past infections. Dr. Garner will discuss clinical lab testing algorithms for specific organism identification and immune response determination. The current CDC recommendations for utilizing both molecular and serology tests and how these can be practically employed by clinical laboratories will also be covered in this presentation.
- Identify current COVID-19 testing status and what might be next for laboratories in the US.
- Defining and fine tuning COVID-19 diagnostic algorithms for both a serological and molecular approach.
- Discuss current testing recommendations and their implementation by one clinical laboratory.
This talk will cover Candida auris infection, colonization, and spread through health care systems from a clinical case perspective. We will discuss clinical lab diagnostics for specific organism identification and how microbiology labs can implement both passive and active surveillance. The talk will also cover current CDC recommendations for limiting the spread of Candida auris.
- Discuss the spread of Candida auris through health care systems.
- Describe how the microbiology laboratory can assist in limiting Candida auris infections.
- Detail the challenges in accurately identifying Candida auris from culture.
Meningitis is an infection of the meninges, the membranes that surround the brain and spinal cord. Encephalitis is inflammation of the brain itself. Anyone can get meningitis or encephalitis and causes include viruses, bacteria, fungus, and parasites. There are a number of diagnostic challenges for identification of patients with meningitis/encephalitis and there have been changes in the epidemiology in recent years. This presentation will review the different etiological agents that cause meningitis and encephalitis as well as provide an overview of the current tools available for diagnosis.
At the conclusion of the presentation, attendees will be able to:
- Describe the difference between meningitis and encephalitis and the challenges with diagnosis.
- Describe the most common causes of meningitis and encephalitis.
- Describe the diagnostic tools used to diagnose meningitis and encephalitis.
CE Units available through Labroots for 6 months after the live event.